| Therapeutic | Ipilimumab |
| Target | CTLA4 |
| Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS |
| Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK |
| 100% seqID Fv Structure | 5tru%3AHL%3Ahl%2F5xj3%3AAB%3ADE%3AJK%3AGH%2F6jc2%3AHL [Fvs: ] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5tru%3AHL%3Ahl%2F5xj3%3AAB%3ADE%3AJK%3AGH%2F6jc2%3AHL [Fvs: ] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | Medarex UltiMAb Mouse |
| INN Year Proposed | 2005 |
| INN Year Recommended | 2006 |
| Companies Involved | Aduro BioTech%3BAIO Studien gGmbH%3BAustralian and New Zealand Urogenital and Prostate Cancer Group%3BBavarian Nordic%3BBig Ten Cancer Research Consortium%3BBioGene Pharmaceutical%3BBristol-Myers Squibb%3BCanadian Cancer Trials Group%3BDana-Farber Cancer Institute%3BEuropean Thoracic Oncology Platform%3BGrupo Espanol Multidisciplinar de Melanoma%3BIcahn School of Medicine at Mount Sinai%3BIntergroupe Francophone de Cancerologie Thoracique%3BLudwig Institute for Cancer Research%3BMassachusetts General Hospital%3BMedarex%3BMemorial Sloan-Kettering Cancer Center%3BNational Cancer Institute %28USA%29%3BNational University Hospital %28Singapore%29%3BNorthwestern University%3BOlivia Newton-John Cancer Research Institute%3BOncoTherapy Science%3BOno Pharmaceutical%3BSidney Kimmel Comprehensive Cancer Center at Johns Hopkins%3BUniversity College London%3BUniversity of California at San Francisco%3BUniversity of Texas M. D. Anderson Cancer Center |
| Conditions Approved | Malignant melanoma%3BRenal cell carcinoma |
| Conditions Active | Colorectal cancer%3BNon-small cell lung cancer%3BGastric cancer%3BGlioblastoma%3BHead and neck cancer%3BMesothelioma%3BOesophageal cancer%3BProstate cancer%3BSmall cell lung cancer%3BUrogenital cancer%3BAdrenocortical carcinoma%3BBreast cancer%3BCNS cancer%3BGastrointestinal cancer%3BGenitourinary disorders%3BGynaecological cancer%3BLiver metastases%3BMeningeal carcinomatosis%3BMyelodysplastic syndromes%3BNeuroendocrine tumours%3BOvarian cancer%3BPancreatic cancer%3BPenile cancer%3BSolid tumours%3BThyroid cancer%3BUveal melanoma%3BDiffuse large B cell lymphoma%3BLiver cancer%3BLung cancer%3BGlioma |
| Conditions Discontinued | HIV infections%3BLymphoma |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
